ReviewPharmacogenomics and personalized medicine2014
MicroRNA binding site polymorphisms as biomarkers in cancer management and research.
Review in Pharmacogenomics and personalized medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- mirSNPs as Potential Colorectal Cancer Biomarkers: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Rs12516 A allele elevates the risk of colorectal cancer via functional CeRNA network of BDNF-AS, miR-4704-5p and BRCA1.BMC cancer · 2026Article
- Sex-Biased CD3ζ 3'-UTR SNP Increased Incidence Risk in Aplastic Anemia.International journal of general medicine · 2024Article
- Impact of MICA 3'UTR allelic variability on miRNA binding prediction, a bioinformatic approach.Frontiers in genetics · 2023Article
- Association of Polymorphism within the Putative miRNA Target Site in the 3'UTR Region of theInternational journal of environmental research and public health · 2022Article
- Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy.Journal for immunotherapy of cancer · 2022Article
- Lectin-Like OLR1 3'UTR Rs1050286 Gene Polymorphism and Plasma Oxidized-LDL in Coronary Artery Disease and Their Relation to Cardiovascular Risk and Outcomes.Reports of biochemistry & molecular biology · 2022Article
- rs12537 Is a Novel Susceptibility SNP Associated With Estrogen Receptor Positive Breast Cancer in Chinese Han Population.Frontiers in medicine · 2021Article
- Association of KLK3, VAMP8 and MDM4 Genetic Variants within microRNA Binding Sites with Prostate Cancer: Evidence from Serbian Population.Pathology oncology research : POR · 2020Article
- Impact of Natural OccurringInternational journal of molecular sciences · 2020Review
- Article
- Genetic Variability in the microRNA Binding Sites ofOncoTargets and therapy · 2020Article
- The KRAS-variant and its impact on normal breast epithelial cell biology.Cell death and differentiation · 2019Article
- Functional microRNA binding site variants.Molecular oncology · 2019Review
- Association between miRNA-binding site polymorphisms in double-strand break repair genes and risk of recurrence in patients with squamous cell carcinomas of the non-oropharynx.Carcinogenesis · 2017Article
- Review
- A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.Journal of cancer research and clinical oncology · 2016Article
- Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcome.Oncotarget · 2016Article
- Review
- Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.Cancer biomarkers : section A of Disease markers · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are important regulators of eukaryotic gene expression. They have been implicated in a broad range of biological processes, and miRNA-related genetic alterations probably underlie several human diseases. Single nucleotide polymorphisms of transcripts may modulate the posttranscriptional regulation of gene expression by miRNAs and explain interindividual variability in cancer risk and in chemotherapy response. On the basis of recent association studies published in the literature, the present review mainly summarizes the potential role of miRNAs as molecular biomarkers for disease susceptibility, diagnosis, prognosis, and drug-response prediction in tumors. Many clues suggest a role for polymorphisms within the 3' untranslated regions of KRAS rs61764370, SET8 rs16917496, and MDM4 rs4245739 as SNPs in miRNA binding sites highly promising in the biology of human cancer. However, more studies are needed to better characterize the composite spectrum of genetic determinants for future use of markers in risk prediction and clinical management of diseases, heading toward personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.